Zhai Yun-kai, Zhu Wei-jun, Hou Hong-li, Sun Dong-xu, Zhao Jie
The first Affiliated Hospital, Zhengzhou University, Zhengzhou, People's Republic of China Henan Engineering Research Center of Digital Medicine, Zhengzhou, People's Republic of China Management Engineering School, Zhengzhou University, Zhengzhou, People's Republic of China.
The first Affiliated Hospital, Zhengzhou University, Zhengzhou, People's Republic of China Henan Engineering Laboratory for Digital Telemedicine Service, Zhengzhou, People's Republic of China.
J Telemed Telecare. 2015 Apr;21(3):123-30. doi: 10.1177/1357633X15571357. Epub 2015 Feb 9.
The aim of this study was to assess the benefits of telemedicine in the delivery of thrombolytic therapy for patients with acute ischemic stroke. We performed a meta-analysis using combinations of the following terms: telestroke, telemedicine, tissue plasminogen activator/t-PA, and acute ischemic stroke. The primary outcome was favorable outcome based on the modified Rankin score. Secondary outcomes were incidence of symptomatic intracranial hemorrhage and overall mortality. We found no significant difference in favorable outcome between the telemedicine and control groups, and no significant difference was found between these groups in the rate of symptomatic intracranial hemorrhage or overall mortality. Patients with acute ischemic stroke who were treated with intravenous thrombolysis had similar outcomes regardless of whether telemedicine was used or they were treated in-person at a medical facility. Telemedicine can be used to support hospitals with limited experience in administering thrombolytic therapy for stroke.
本研究的目的是评估远程医疗在为急性缺血性中风患者提供溶栓治疗方面的益处。我们使用以下术语组合进行了一项荟萃分析：远程中风、远程医疗、组织纤溶酶原激活剂/t-PA以及急性缺血性中风。主要结局是基于改良Rankin量表的良好结局。次要结局是症状性颅内出血的发生率和总体死亡率。我们发现远程医疗组和对照组在良好结局方面无显著差异，在症状性颅内出血率或总体死亡率方面两组也无显著差异。接受静脉溶栓治疗的急性缺血性中风患者，无论是否使用远程医疗，还是在医疗机构接受面对面治疗，其结局相似。远程医疗可用于为在实施中风溶栓治疗方面经验有限的医院提供支持。
